Cargando…

Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers

BACKGROUND: The programmed death-ligand 1 inhibitor atezolizumab had shown clinical activity against several advanced malignancies. PATIENTS AND METHODS: This phase II, open-label basket study (NCT02458638) was conducted in 16 main cohorts of patients aged ≥18 years with stage III or IV solid tumors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tabernero, J., Andre, F., Blay, J.-Y., Bustillos, A., Fear, S., Ganta, S., Jaeger, D., Maio, M., Mileshkin, L., Melero, I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058880/ https://www.ncbi.nlm.nih.gov/pubmed/35305400 http://dx.doi.org/10.1016/j.esmoop.2022.100419

Ejemplares similares

Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study
por: Sherman, E., et al.
Publicado: (2023)

An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors
por: Taylor, Kirsty, et al.
Publicado: (2020)

Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors
por: Mizugaki, Hidenori, et al.
Publicado: (2016)

Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial
por: Ferreiro-Pantín, M., et al.
Publicado: (2023)

Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
por: Friedman, Claire F, et al.
Publicado: (2020)

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study
por: Simonelli, M., et al.
Publicado: (2022)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
por: Bando, Hideaki, et al.
Publicado: (2020)

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours
por: Ebata, Takahiro, et al.
Publicado: (2019)

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma
por: Patnaik, A, et al.
Publicado: (2014)

Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
por: Yamazaki, N., et al.
Publicado: (2015)

An open-label, multicohort Phase Ib trial of pembrolizumab (MK-3475) for advanced hematologic malignancies: KEYNOTE-013
por: Ribrag, Vincent, et al.
Publicado: (2015)

Multicohort analysis of the maternal age effect on recombination
por: Martin, Hilary C., et al.
Publicado: (2015)

Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
por: Li, Dan-Ni, et al.
Publicado: (2021)

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
por: Hack, Stephen P., et al.
Publicado: (2021)

Comprehensive Lipidomic Workflow for Multicohort Population Phenotyping Using Stable Isotope Dilution Targeted Liquid Chromatography-Mass Spectrometry
por: Ryan, Monique J., et al.
Publicado: (2023)

Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial
por: Kim, Tae Won, et al.
Publicado: (2023)

Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
por: Katayama, Yuki, et al.
Publicado: (2020)

Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union
por: Patel, Hina, et al.
Publicado: (2021)

Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study
por: Qu, Yuan-Yuan, et al.
Publicado: (2022)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Phase II study of concomitant radiotherapy with atezolizumab in oligometastatic soft tissue sarcomas: STEREOSARC trial protocol
por: le Guevelou, Jennifer, et al.
Publicado: (2020)

Inflammatory biomarkers and motoric cognitive risk syndrome: Multicohort survey
por: Groeger, Justina L, et al.
Publicado: (2022)

Solid phase transformations II
por: Čermák, J, et al.
Publicado: (2009)

Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer
por: Imai, Hisao, et al.
Publicado: (2022)

The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer
por: Kasajima, Masashi, et al.
Publicado: (2023)

The feasibility of triggers for the integration of Standardised, Early Palliative (STEP) Care in advanced cancer: A phase II trial
por: Collins, Anna, et al.
Publicado: (2022)

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
por: Turner, Nicholas C, et al.
Publicado: (2020)

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors
por: Blank, Christian U., et al.
Publicado: (2021)

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial
por: Chaft, Jamie E., et al.
Publicado: (2022)

Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression
por: Zhang, Chuan, et al.
Publicado: (2023)

Determining the timing of pubertal onset via a multicohort analysis of growth
por: Syrjälä, Essi, et al.
Publicado: (2021)

The Southern European Atlantic Diet and depression incidence: a multicohort study
por: Carballo-Casla, A, et al.
Publicado: (2022)

Relationship between dietary pattern and depressive symptoms: an international multicohort study
por: Wu, Hanzhang, et al.
Publicado: (2023)

The Southern European Atlantic diet and depression risk: a European multicohort study
por: Carballo-Casla, Adrián, et al.
Publicado: (2023)

Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
por: Yap, Timothy A., et al.
Publicado: (2020)

Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
por: Hellmann, Matthew D., et al.
Publicado: (2020)

Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumors
por: Saal, Jonas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uiakgg0vq4e3c5in4nq2nbq8j5